Product Description and Benefits
  Indications for Use / Contraindications
  Product Makeup/Histology
  Clinical Sequence


Previous | Next Next


In this section, you have learned:

  • INTEGRA™ Meshed Bilayer Wound Matrix is indicated for the management of wounds including partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, surgical wounds (donor sites/grafts, post-Moh’s surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns, and skin tears) and draining wounds. INTEGRA™ Meshed Bilayer Wound Matrix may be used in conjunction with negative pressure wound therapy. The device is intended for one-time use.

  • INTEGRA™ Meshed Bilayer Wound Matrix is an advanced wound care device comprised of a porous matrix of cross-linked bovine tendon collagen and glycosaminoglycan. The collagen glycosaminoglycan biodegradable matrix provides a scaffold for cellular invasion and capillary growth. The meshed bilayer matrix allows drainage of wound exudate and provides a flexible adherent covering for the wound surface.

  • The wound is surgically debrided or excised to viable tissue and INTEGRA™ Meshed Bilayer Wound Matrix is applied. Over the next 2-4 weeks, the matrix is remodeled as the patient's cells rebuild the damaged site while simultaneously degrading the collagen-GAG matrix. For larger wounds, a thin epidermal autograft 0.004-0.006 inches (0.1016 - 0.1524 millimeters) may be applied. Wound closure is typically complete in about 30 days.
You have successfully completed "Introduction to INTEGRA™ Meshed Bilayer Wound Matrix." To continue your review of all sections in the COURSE click "NEXT", otherwise click on the below link.


Previous | Next Next

© Copyright 2010 Integra LifeSciences Corporation. All Rights Reserved.
Terms of Use • Privacy Policy